Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy (MA-23)
NCT ID: NCT00555737
Last Updated: 2019-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
102 participants
OBSERVATIONAL
2003-11-30
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Enteroscopy for Early Diagnosis of Tumors in Celiac Disease
NCT02325232
Comparison Between Axial- and Lateral-viewing Capsule Endoscopy in Celiac Disease
NCT03095573
Treatment of Screen-detected Celiac Disease
NCT01116505
Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
NCT05810441
Treatment of Mild Enteropathy Celiac Disease
NCT00628823
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
These changes cause a loss of absorptive capacity which in turn leads to variable degrees of malabsorption. A person suffering from celiac may have symptoms ranging from mild iron deficiency anemia to severe diarrhea and weight loss. Characteristically, removal of gluten from the diet is followed by resolution of the mucosal changes and the symptoms.
Celiac disease is suspected on the basis of clinical signs and symptoms, and is generally confirmed by serological testing and small bowel biopsy. Patients with suspected celiac disease undergo upper GI endoscopy with mucosal biopsy of the duodenum, in order to detect the characteristic histological changes.
Although the main role for endoscopy in GSE is to obtain tissue for histological examination, a variety of endoscopic changes have been described in these patients,such as nodularity of the mucosa and 'scalloping' or loss of the duodenal mucosal folds.
The GivenĀ® Diagnostic System can visually investigate the small bowel, producing high-quality images of the mucosa, which might be able to detect villous atrophy and thus could be used in the assessment of patients with GSE. Whereas upper GI endoscopy is invasive, often requires sedation and may be uncomfortable, Capsule Endoscopy is less invasive, convenient to use and does not require sedation.
Capsule Endoscopy could become an important tool for the non-invasive assessment of small bowel mucosa in GSE.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capsule Endoscopy
GivenĀ® Diagnostic system with Pillcam SB
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient agrees to sign the Informed Consent Form
* Patient has positive celiac serology or negative celiac serology + IgA deficiency and suffers from one or more of the following symptoms and/or abdominal biochemical values:
1. Chronic diarrhea
2. Weight loss
3. Abdominal cramps
4. History of spontaneous abortion
5. Iron deficiency anemia
6. Osteoporosis
7. Infertility
8. Hypoalbuminaemia
9. Low cholesterol
10. Low prothrombin activity
Exclusion Criteria
* Patient has a cardiac pacemaker or other electro-medical device.
* Patient suffers from severe swallowing disorder or Zenker's diverticulum
* Patient has any condition, which precludes compliance with study and/or device instructions.
* Female patient is pregnant
* Patient suffers from life threatening conditions
* Patient is currently participating in another clinical study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic - MITG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Given Imaging Ltd.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roberto de Franchis, MD, Prof.
Role: PRINCIPAL_INVESTIGATOR
Ospedale Maggiore - Policlinico, Milano, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts, United States
University of Tampere Medical School
Tampere, , Finland
Ospedale Maggiore - Policlinico
Milan, , Italy
Universita Cattolica del Sacro Cuore
Rome, , Italy
San Giovanni A.S. Hospital
Torino, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MA-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.